Telaprevir: Phase II started

Vertex began a Phase II trial to evaluate twice-daily 100 or 400 mg VX-222 plus telaprevir with or without Pegasys peginterferon alfa-2a and ribavirin in 100 treatment-naïve patients with HCV genoty...